{
  "docId": "019de074-7bfd-70c0-985e-370853614892",
  "docSlug": "be9cd2ecd1a9b4702566620e9f2aa170",
  "documentTitle": "Bionomics | Results Presentation Deck | 27 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 27,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7bfd-70c0-985e-370853614892/4",
  "deckHref": "/decks/019de074-7bfd-70c0-985e-370853614892",
  "deckJsonHref": "/decks/019de074-7bfd-70c0-985e-370853614892.json",
  "deckAnchorHref": "/decks/019de074-7bfd-70c0-985e-370853614892#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.44
      },
      "kind": "list",
      "text": "Has achieved clinical Proof of Target Engagement (PTE), Proof of Mechanism (PoM) in panic model setting and Proof of Concept (PoC) in Generalized Anxiety Disorder (GAD)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c7f7d28-bb77-4dac-8405-c27a161208c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "list",
      "text": "Extensive safety database from 13 clinical trials completed to date with exposure in over 500 subjects supporting a non-sedating, non-addicting anxiolytic profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cf7c7c0-542c-48ba-80fd-45076673168c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.94,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "list",
      "text": "In development for underserved markets with >22 million patients in the US alone suffering from SAD and PTSD and no new FDA approved therapies in nearly two decades; peak annual sales for acute SAD of ~$1.7B and for chronic PTSD of ~$2.6B",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "214396bc-f217-4875-b4c9-d3ff100cecda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "list",
      "text": "Novel negative allosteric modulator of α7 nAChR for treatment of anxiety and stressor-related disorders",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95d2f971-d441-4e04-9e5f-2c066de27aa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.73
      },
      "kind": "list",
      "text": "Strong proprietary protection with patent coverage through late 2030's",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a55c20d9-343e-4379-ae52-6ba68a6a3da2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "With a Profile Compatible as an Acute Non-Sedating Anxiolytic",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b50c1464-23ff-48d6-848d-6e645f75f98f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.55,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210: A Best-In-Class Development Candidate",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc05c3df-e77e-4005-b30c-c620dd85f6f1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d9f983ee-3ce9-4419-9a4d-c4e5f0bbee61",
      "evidence": "list/bullet: In development for underserved markets with >22 million patients in the US alone suffering from SAD and PTSD and no new FDA approved therapies in nearly two decades; peak annual sales for acute SAD of ~$1.7B",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 1,
      "beatId": "52a50e6e-c8d3-406a-b3e4-1e2e539f6675",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document introduces the problem of anxiety disorders and the need for effective treatments.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}